The first new TB medicines in over 40 years—bedaquiline (Sirturo™)  and delamanid (Deltyba™) —were recently released onto the market for the treatment of multidrug-resistant tuberculosis (MDR-TB). On this website, you will find general information and guidance documents about the new medicines and regimens, information on active surveillance of new TB medicines, training materials and clinician management resources from globally recognized bodies such as the World Health Organization.

This website is designed to be a starting point for countries that plan to use new TB medicines; however, it is not all encompassing. For more comprehensive technical assistance on any areas of new TB medicine adoption, contact us via email at

What is Bedaquiline?

Bedaquiline is a new antibacterial medicine used for the treatment of MDR-TB.

More Info

Before You Begin Implementation

The Getting Started guide provides generic guidance on how to implement the new drug(s) in country.

More Info

How to Conduct Active Surveillance of TB Meds

Guidance and information is provided on the WHO recommended active pharmacovigilance and management of adverse drug reactions for new TB medicines.

More Info

“Bedaquiline is the chance for survival for quite a number of TB patients who already lost their hope”

-Nana Kiria, Deputy Director of the National Center of Tuberculosis and Lung diseases, Georgia